http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210134241-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01L2200-0663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2527-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2563-107 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-701 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6844 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 |
| filingDate | 2021-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210134241-A |
| titleOfInvention | Method of identifying severe acute respiratory syndrome corona virus 2 (sars-cov-2) ribonucleic acid (rna) |
| abstract | A method for detecting the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a biological sample comprises the steps of: dissolving the biological sample to form a lysate; and a forward primer having an oligonucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, and SEQ ID NO: 17; a reverse primer having an oligonucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, and SEQ ID NO: 18; and a nucleic acid sequence for a target nucleic acid sequence in lysate in the presence of a molecular beacon having an oligonucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15 and SEQ ID NO: 19 and a fluorophore - generating an amplified lysate by performing amplification of the base (NASBA). The amplified lysate is exposed to an excitation source. Fluorescence of the fluorophore is detected in the amplified lysate exposed to the excitation source. The presence of SARS-CoV-2 in the biological sample is determined in response to detecting the fluorescence of the fluorophore. |
| priorityDate | 2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.